SecBot SecBot
Biotech Drug Report Generated Nov 5, 2026

TRUXIMA

TEVA·TEVA PHARMACEUTICAL INDUSTRIES LTD
NEUTRAL
Drug Impact Rating4/10
Trial phase
Approved
Time to market
Already approved and commercially available since November 2018 (oncology) and December 2019 (rheumatoid arthritis).
Why 4/10
TRUXIMA is already approved and commercially marketed with no pending PDUFA date or pivotal readout in the next 12 months; the most recent binary catalyst (interchangeability designation) occurred on July 1, 2026. As an approved product within a large, diversified pharma company, there is no single hard dated catalyst to drive a major share-price move from this drug alone.
Actionable Insight NEUTRAL

TRUXIMA's next catalyst is the expiration of its first-interchangeable exclusivity period, which runs approximately 1 year from the July 1, 2026 FDA designation. Watch for whether a second interchangeable rituximab biosimilar (e.g. from Fresenius Kabi/Dr. Reddy's, approved August 2026) can enter the interchangeable market after that window closes. Also monitor Teva's Q4 2026 and full-year 2026 earnings for biosimilars revenue tracking against the $800M+ target.

Price Chart

Loading chart...

Executive Summary

TRUXIMA (rituximab-abbs) is a biosimilar to Roche/Genentech's Rituxan, developed by South Korea's Celltrion and exclusively commercialized in the U.S. and Canada by Teva Pharmaceutical Industries (NYSE: TEVA) under a partnership dating to October 2016. First FDA-approved in November 2018 for non-Hodgkin lymphoma, it now covers all Rituxan indications including CLL, rheumatoid arthritis, vasculitis, and pemphigus vulgaris. In July 2026, TRUXIMA became the first rituximab biosimilar to receive FDA interchangeability designation, granting it a roughly 1-year exclusivity period during which pharmacists can substitute it for the reference product without a new prescription. However, a competing rituximab biosimilar from Fresenius Kabi and Dr. Reddy's was approved in August 2026, and Teva's overall generics revenue continues to face headwinds. TRUXIMA is one component of Teva's biosimilars portfolio, which is tracking toward exceeding $800 million in 2026 revenue, but Teva is a large diversified pharma (Q3 2026 revenue $4.4B) for which no single product is a make-or-break catalyst.

How It Works

TRUXIMA is a biosimilar (a nearly identical copy) of Rituxan (rituximab), a monoclonal antibody that targets the CD20 protein found on the surface of certain immune B-cells. By binding to CD20, it helps the immune system destroy cancerous B-cells in lymphomas and leukemias, and also reduces harmful B-cell activity in autoimmune diseases like rheumatoid arthritis and vasculitis.

Trial Status

TRUXIMA is fully FDA-approved across all indications of its reference product Rituxan. The most recent regulatory milestone was the FDA granting interchangeability designation on July 1, 2026, making it the first interchangeable rituximab biosimilar in the U.S.

The Two-Sided Case

▲ Bull Case5
TRUXIMA became the first interchangeable rituximab biosimilar in the U.S. in July 2026, enabling pharmacy-level substitution without prescriber involvement, a significant commercial advantage.
The interchangeability designation grants TRUXIMA a roughly 1-year exclusivity period during which the FDA cannot approve another interchangeable rituximab biosimilar, protecting market position.
Teva's biosimilars portfolio (which includes TRUXIMA) is on track to exceed $800 million in 2026 revenue, achieving its original 2027 target one year early.
TRUXIMA was the first FDA-approved rituximab biosimilar (November 2018) and has a multi-year head start in brand recognition and physician adoption.
Teva's Q3 2026 earnings beat estimates (EPS $0.86 vs $0.72 consensus) and analyst consensus on TEVA is Strong Buy with a mean price target of $47.92, implying ~14% upside.
▼ Bear Case4
New competition entered in August 2026: Fresenius Kabi and Dr. Reddy's received FDA approval for a separate rituximab biosimilar, which will pressure pricing and market share.
Teva's overall generics revenue declined 2% YoY in Q3 2026, and TRUXIMA sits within the generics/biosimilars segment that faces ongoing pricing erosion.
TRUXIMA is commercialized through a partnership with Celltrion (exclusive U.S./Canada rights since 2016), meaning Teva shares economics with its partner rather than keeping full margins.
The interchangeability exclusivity period is time-limited (roughly 1 year from July 2026), after which other interchangeable rituximab biosimilars could enter the market.

Upcoming Catalysts

  • Teva Q4 2026 and full-year 2026 earnings (early 2027) to report biosimilars revenue progress against the $800M+ target
  • Expiration of TRUXIMA's first-interchangeable exclusivity period (approximately mid-2027), which could open the door for competing interchangeable rituximab biosimilars
  • Potential label expansion or new indication filings for TRUXIMA as the reference product Rituxan's patent landscape evolves

Source Filing

The SecBot filing or press-release report that triggered this drug report:

TEVA PHARMACEUTICAL INDUSTRIES LTD 8-K TEVA ·Originating report

Sources · 14

Hover a chip for the title
1 bigmoleculewatch.com2 pearceip.law3 fda.gov4 tevausa.com5 tevapharm.com6 jdsupra.com7 thestar.com8 seekingalpha.com9 msn.com10 drugs.com11 tevapharm.com12 sec.gov13 truxima.com14 truximahcp.com